Daily Walnut Consumption Linked to Mood Boost and Serotonin Metabolism Shifts

A recent scientific investigation sheds light on how incorporating a daily serving of walnuts into your routine may positively influence emotional well-being. Published in the journal Food & Function, an eight-week crossover trial evaluated whether eating walnuts daily alters mood states in young adults, while also measuring associated shifts in serotonin-related and gut-derived metabolites.

Understanding the Connection Between Diet and Mental Health

Mental health disorders affect a significant portion of the global population, prompting researchers to explore lifestyle factors like diet that may support mental well-being. Because the brain requires substantial energy and specific nutrients to function optimally, dietary choices have become a focal point in nutritional psychiatry.

Serotonin is a vital neurotransmitter responsible for mood regulation, synthesized primarily from the dietary amino acid tryptophan. To track serotonin activity, researchers often measure its main metabolite, 5-hydroxyindoleacetic acid (5-HIAA), through urine samples. Meanwhile, walnuts are packed with omega-3 fatty acids, fiber, tryptophan, and beneficial polyphenols called ellagitannins. When consumed, gut microbiota convert these plant compounds into metabolites known as urolithins, offering a biological marker of walnut intake.

Putting Daily Walnut Intake to the Test

Researchers from the University of Barcelona designed an 18-week open-label randomized crossover trial involving healthy adults aged 20 to 35. Out of 84 screened candidates, 36 participants met the strict inclusion criteria—such as a healthy body mass index (BMI) and moderate physical activity levels—and 31 participants successfully completed both arms of the trial.

During the intervention periods, participants were randomly assigned to either consume 40 grams of walnuts daily with dinner or completely avoid nuts and nut products for eight weeks. Following a two-week washout period, participants crossed over to the alternative condition. Throughout both phases, participants received guidance from a nutritionist to maintain a standardized Mediterranean-style diet.

To evaluate outcomes, researchers assessed mood states using the Profile of Mood States Questionnaire (POMS), while first-morning urine samples were collected to measure 5-HIAA, cortisol, and urolithins using advanced laboratory techniques.

Key Findings on Mood and Metabolites

The trial revealed notable differences between the walnut and control periods. Specifically, participants experienced a measurable reduction in total mood disturbance during the walnut-supplemented phase, scoring an average of 4.85 points lower than during the control condition. Although initial assessments hinted at reductions in anger, fatigue, and specific food-craving domains, these specific changes did not remain statistically significant after correcting for multiple comparisons.

Biochemical analyses of urine samples provided further insight into potential biological mechanisms. Researchers observed a significant increase in urinary 5-HIAA levels during the walnut consumption period, and higher concentrations of this serotonin metabolite correlated with lower total mood disturbance. Additionally, participants exhibited significantly higher concentrations of urinary urolithin A and urolithin B, which also correlated with concurrent increases in urinary 5-HIAA. Cortisol levels and perceived stress, however, showed no significant differences between the two conditions.

Interpreting the Results and Limitations

While these findings point to an association between daily walnut consumption, gut-derived urolithins, and whole-body serotonin metabolism, the study authors emphasize certain limitations. Because the trial did not directly measure brain serotonin or central nervous system function, the observed associations cannot definitively establish a direct neurological mechanism. Furthermore, the relatively small sample size, predominantly female participant group, and open-label design mean that further research involving larger, more diverse populations and longer durations is necessary to confirm these health benefits.

Source: News-Medical.net